Status:
COMPLETED
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
Lead Sponsor:
AstraZeneca
Conditions:
Hypercholesterolemia
Coronary Heart Disease
Eligibility:
All Genders
18-75 years
Brief Summary
In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a d...
Eligibility Criteria
Inclusion
- patients who had not been treated with cholesterol lowering drugs at least in the past three months, with an LDL-C 3.2 mmol/l.
- According to the advise of the CBO, and could be included in one of the following risk groups: secondary prevention, DM or primary prevention.
- The general practice investigator made the decision to start treatment with rosuvastatin irrespective of study participation.
- Patient approved to place anonymous results at the disposal of AstraZeneca
Exclusion
- Patients with symptoms of myalgia, myopathy or liver function insufficiency (including raised serum transaminases) which bear a causal relation to the treatment with statins, patients with familiar dyslipidemia and/or patients with contra-indications for treatment with rosuvastatin
Key Trial Info
Start Date :
May 1 2003
Trial Type :
OBSERVATIONAL
End Date :
April 1 2005
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00660764
Start Date
May 1 2003
End Date
April 1 2005
Last Update
March 16 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.